The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | L | Antineoplastic and immunomodulating agents | |
| 2 | L01 | Antineoplastic agents | |
| 3 | L01F | Monoclonal antibodies and antibody drug conjugates | |
| 4 | L01FE | EGFR (Epidermal Growth Factor Receptor) inhibitors | |
| 5 | L01FE02 | Panitumumab |
| Active Ingredient | Description | |
|---|---|---|
| Panitumumab |
Panitumumab is a recombinant, fully human IgG2 monoclonal antibody that binds with high affinity and specificity to the human EGFR. Panitumumab binds to the ligand binding domain of EGFR and inhibits receptor autophosphorylation induced by all known EGFR ligands. Binding of panitumumab to EGFR results in internalisation of the receptor, inhibition of cell growth, induction of apoptosis, and decreased interleukin 8 and vascular endothelial growth factor production. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| VECTIBIX Concentrate for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
